A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis

Ilvira M. Khan(The University of Texas MD Anderson Cancer Center), Laura Beretta(The University of Texas MD Anderson Cancer Center), Hashem B. El‐Serag(Baylor College of Medicine), Donjeta Gjuka(The University of Texas MD Anderson Cancer Center), Jingjing Jiao(Second Affiliated Hospital of Zhejiang University), Jing Wang(The University of Texas MD Anderson Cancer Center), Ying Wang(Central South University), Jorge A. Marrero(University of Pennsylvania), Xiaoling Song(Fred Hutch Cancer Center), Peng Wei(Creighton University)
Cancer Prevention Research
March 8, 2021
10.1158/1940-6207.capr-20-0600
Cited by 15

Related Papers

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930